Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Demographic characteristics and baseline frailty status. | Frailty status at baseline | Characteristics | Robust (n = 158) | Pre‐frail (n = 153) | Frail (n = 13) | p‐value: Vitamin D status (25‐hydroxyvitamin D), (ng/mL) | | | | 0.969
Source: Results table. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Cohort study.
Cohort study
Examines exposures and outcomes over time within a defined group.
Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
We conducted a prospective cohort study among PWH aged ≥50 years in Bangkok, Thailand, between May 2015 and June 2024.
Source: Abstract.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Frailty Transition Among Older Adults Living With HIV in Thailand: A 5‐Year Longitudinal Study
Cohort study · Journal of the International AIDS Society · 2026
Original publication title
Frailty Transition Among Older Adults Living With HIV in Thailand: A 5‐Year Longitudinal Study
© 2026 The Author(s). Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What background does the paper provide?
Frailty is highly prevalent among older people with HIV (PWH), driven by multimorbidity and HIV‐associated accelerated ageing. We investigated frailty transitions and associated factors over a 5‐year follow‐up period in an ageing cohort of PWH in Thailand.
Source: IntroductionAbstract: What methods does the paper describe?
We conducted a prospective cohort study among PWH aged ≥50 years in Bangkok, Thailand, between May 2015 and June 2024. Frailty phenotypes were assessed at baseline and at 5 years of follow‐up using the Fried frailty phenotype, including unintentional weight loss, low physical activity, exhaustion, weak grip strength and slow walking speed. Multinomial logistic regression was performed to identify factors associated with frailty progression and reversibility over follow‐up.
Source: MethodsAbstract: Results
Among 324 participants enrolled (63% male; median age of 54 [IQR, 52−59] years), 158 (49%) were robust, 153 (47%) were pre‐frailty and 13 (4%) were frailty at baseline. Over 5 years, 111 participants (34%) experienced frailty worsening, 158 (49%) remained stable and 55 (17%) demonstrated frailty reversal. Among 158 PWH who were robust at baseline, 75 (47%) remained robust, 57 (36%) transitioned to pre‐frailty and 26 (16%) progressed to frailty. Notably, among those frail at baseline (N = 13), 65% improved to pre‐frailty or robustness.
Low physical activity was the most common frailty component at baseline, while weak grip strength was the most predominant frailty phenotype at year 5. In multivariable analysis, multimorbidity (adjusted odds ratio [aOR] 3.09, 95% confidence interval [CI]: 1.42−6.72, p = 0.004), antiretroviral therapy (ART) duration>20 years (aOR 1.82, 95% CI: 1.08−3.06, p = 0.025) and baseline vitamin D deficiency (aOR 1.85, 95% CI: 1.10−3.10, p = 0.019) were independently associated with increased frailty over the 5‐year follow‐up. Conversely, multimorbidity (aOR 0.44, 95% CI: 0.44 [0.23−0.84], p = 0.013) and CD4 counts< 500 cells/mm3 (aOR 0.25, 95% CI: 0.10−0.62, p = 0.003) were associated with a lower likelihood of frailty reversal.
Source: ResultsAbstract: Conclusions
Frailty among PWH aged ≥50 years in Thailand was common and highly dynamic, with over half of frail participants improving over 5 years. Multimorbidity, prolonged ART exposure and vitamin D deficiency were key predictors of frailty progression, whereas CD4< 500 cells/mm3 and multimorbidity reduced the likelihood of frailty reversal. These findings highlight frailty as modifiable and support integrating routine frailty screening and geriatric‐informed care into long‐term HIV services.
Source: ConclusionsAuthors’ abstract
ABSTRACT
Introduction
Frailty is highly prevalent among older people with HIV (PWH), driven by multimorbidity and HIV‐associated accelerated ageing. We investigated frailty transitions and associated factors over a 5‐year follow‐up period in an ageing cohort of PWH in Thailand.
Methods
We conducted a prospective cohort study among PWH aged ≥50 years in Bangkok, Thailand, between May 2015 and June 2024. Frailty phenotypes were assessed at baseline and at 5 years of follow‐up using the Fried frailty phenotype, including unintentional weight loss, low physical activity, exhaustion, weak grip strength and slow walking speed. Multinomial logistic regression was performed to identify factors associated with frailty progression and reversibility over follow‐up.
Results
Among 324 participants enrolled (63% male; median age of 54 [IQR, 52−59] years), 158 (49%) were robust, 153 (47%) were pre‐frailty and 13 (4%) were frailty at baseline. Over 5 years, 111 participants (34%) experienced frailty worsening, 158 (49%) remained stable and 55 (17%) demonstrated frailty reversal. Among 158 PWH who were robust at baseline, 75 (47%) remained robust, 57 (36%) transitioned to pre‐frailty and 26 (16%) progressed to frailty. Notably, among those frail at baseline (N = 13), 65% improved to pre‐frailty or robustness.
Low physical activity was the most common frailty component at baseline, while weak grip strength was the most predominant frailty phenotype at year 5. In multivariable analysis, multimorbidity (adjusted odds ratio [aOR] 3.09, 95% confidence interval [CI]: 1.42−6.72, p = 0.004), antiretroviral therapy (ART) duration>20 years (aOR 1.82, 95% CI: 1.08−3.06, p = 0.025) and baseline vitamin D deficiency (aOR 1.85, 95% CI: 1.10−3.10, p = 0.019) were independently associated with increased frailty over the 5‐year follow‐up. Conversely, multimorbidity (aOR 0.44, 95% CI: 0.44 [0.23−0.84], p = 0.013) and CD4 counts< 500 cells/mm3 (aOR 0.25, 95% CI: 0.10−0.62, p = 0.003) were associated with a lower likelihood of frailty reversal.
Conclusions
Frailty among PWH aged ≥50 years in Thailand was common and highly dynamic, with over half of frail participants improving over 5 years. Multimorbidity, prolonged ART exposure and vitamin D deficiency were key predictors of frailty progression, whereas CD4< 500 cells/mm3 and multimorbidity reduced the likelihood of frailty reversal. These findings highlight frailty as modifiable and support integrating routine frailty screening and geriatric‐informed care into long‐term HIV services.
Clinical Trial Registration
NCT00411983
Publication and source details
Original title: Frailty Transition Among Older Adults Living With HIV in Thailand: A 5‐Year Longitudinal Study
Tanakorn Apornpong; Win Min Han; Akarin Hiransuthikul; Hay Mar Su Lwin; Napon Hiranburana; Sasiwimol Ubolyam; Stephen J. Kerr; Thira Woratanarat; Anchalee Avihingsanon; HIV‐NAT 006 and 207 study team
Journal of the International AIDS Society · 2026
© 2026 The Author(s). Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. Government Research Budget year 2015 GRB‐APS‐12‐58‐30‐09GRB‐APS‐04‐59‐30‐03 Ratchadapiseksompotch Fund RA68/010 Second Century Fund (C2F)Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-10T23:33:03.992483+00:00
DOI: 10.1002/jia2.70099 · PMC13140913